Goserelin Acetate

• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting
  2024-512926-27-00 Phase III 7 countries Medica Scientia Innovation Research S.L.; Stemline Therapeutics Inc.
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial Recruiting
  2022-501551-90-00 Phase II/III 2 countries Ziekenhuis Aan De Stroom
• A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip… Recruiting
  2023-507305-33-00 Phase I (FiH) 1 country Astrazeneca AB
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting
  2023-505871-63-00 Phase III 13 countries Olema Pharmaceuticals Inc.
• Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol… Recruiting
  2023-506698-36-00 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting
  2022-502046-28-00 Phase III 7 countries F. Hoffmann-La Roche AG
• Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence… Recruiting
  2024-517666-41-00 Phase III 1 country Instituto De Investigacion En Oncología Radioterapica FEOR
• Phase II Dutasteride in combination with CAB vs CAB in SDC (DUCT) Recruiting
  2022-500745-24-00 Phase II/III 1 country Stichting Radboud University Medical Center
• Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial t… Recruiting
  2022-502373-42-00 Phase III 1 country UZ Leuven
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 Phase IV 1 country Grupo Espanol De Investigacion En Cancer De Mama
• A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) w… Ended
  2024-512023-37-00 Phase II 1 country Ziekenhuis Aan De Stroom
• A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended
  2022-502634-52-00 Phase III 2 countries Friedrich-Schiller-Universitaet Jena
• DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended
  2023-509494-23-00 Phase II 1 country Institut Bergonie
• A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore… Ended
  2024-514891-41-00 Phase IV 5 countries Novartis Pharma AG
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended
  2023-503990-39-00 Phase III 12 countries AstraZeneca AB
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended
  2023-503995-26-00 Phase III 13 countries AstraZeneca AB
• Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive,… Ended
  2024-516847-23-00 Phase II 3 countries Unicancer
• Darolutamide vs ADT in hormone naïve Pca Ended
  2024-510840-30-00 Phase II 4 countries European Organisation For Research And Treatment Of Cancer

Showing 1–18 of 18 trials